Muftuoglu Orkun, Prasher Pawan, Chu Claire, Mootha V Vinod, Verity Steven M, Cavanagh H Dwight, Bowman R Wayne, McCulley James P
Department of Ophthalmology, University of Texas Southwestern Medical Center, Dallas, Texas 75390-9057, USA.
J Cataract Refract Surg. 2009 Jun;35(6):1063-71. doi: 10.1016/j.jcrs.2009.01.028.
To evaluate the visual and refractive outcomes of laser in situ keratomileusis (LASIK) to correct residual refractive error after apodized diffractive multifocal intraocular lens (IOL) implantation.
University of Texas Southwestern Medical Center, Dallas, Texas, USA.
This retrospective study reviewed eyes of consecutive patients who had LASIK using the IntraLase FS60 femtosecond laser and Visx Star S4 excimer laser to correct residual refractive error after AcrySof ReSTOR IOL implantation.
The review comprised 85 eyes of 59 patients. Thirty-six eyes (42.3%) had myopic correction, 35 (41.2%) had mixed astigmatic correction, and 14 (16.5%) had hyperopic correction; 45 eyes (52.9%) also had neodymium:YAG (Nd:YAG) capsulotomy. Six months after LASIK, 91.8% of eyes had an uncorrected distance visual acuity (UCVA) of 20/25 or better, 92.9% had an uncorrected near visual acuity (UCNVA) of J1 or better, and 85.9% had 20/25 or better UCVA concurrent with J1 or better UCNVA. No eye lost more than 1 line of best spectacle-corrected visual acuity; 2 eyes (2.4%) lost 1 line. Ninety-nine percent of eyes were within +/-1.00 diopter (D) of emmetropia, and 98% of eyes were within +/-1.00 D cylinder. There was no significant difference in postoperative UCVA or UCNVA between the 3 refraction groups (P >.05) or between eyes that had Nd:YAG capsulotomy and those that did not (P >.05).
Laser in situ keratomileusis for residual ametropia after apodized diffractive multifocal IOL implantation was predictable, effective, and safe.
评估准分子原位角膜磨镶术（LASIK）矫正变迹衍射多焦点人工晶状体（IOL）植入术后残余屈光不正的视觉和屈光效果。
美国德克萨斯州达拉斯市德克萨斯大学西南医学中心。
这项回顾性研究纳入了连续接受LASIK手术的患者的眼睛，使用IntraLase FS60飞秒激光和Visx Star S4准分子激光矫正AcrySof ReSTOR IOL植入术后的残余屈光不正。
该回顾包括59例患者的85只眼。36只眼（42.3%）进行了近视矫正，35只眼（41.2%）进行了混合散光矫正，14只眼（16.5%）进行了远视矫正；45只眼（52.9%）还进行了钕：钇铝石榴石（Nd:YAG）晶状体后囊切开术。LASIK术后6个月，91.8%的眼睛未矫正远视力（UCVA）达到20/25或更好，92.9%的眼睛未矫正近视力（UCNVA）达到J1或更好，85.9%的眼睛UCVA达到20/25或更好且UCNVA达到J1或更好。没有眼睛的最佳矫正视力下降超过1行；2只眼（2.4%）下降了1行。99%的眼睛屈光不正度数在正视眼的±1.00屈光度（D）范围内，98%的眼睛散光度数在±1.00 D柱镜范围内。3个屈光组之间（P>.05）或进行Nd:YAG晶状体后囊切开术的眼睛与未进行该手术的眼睛之间（P>.05），术后UCVA或UCNVA没有显著差异。
准分子原位角膜磨镶术用于矫正变迹衍射多焦点IOL植入术后的残余屈光不正具有可预测性、有效性和安全性。
